Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

被引：0

作者：

Michael A Postow

Diana M Cardona

Janis M Taube

Robert A Anders

Clive R Taylor

Jedd D Wolchok

Margaret K Callahan

Michael A Curran

Alexander M Lesokhin

Joseph F Grosso

Christine E Horak

John Cogswell

Jason S Simon

Ashok K Gupta

Mario Sznol

机构：

[1] Memorial Sloan-Kettering Cancer Center,Keck School of Medicine

[2] Duke University School of Medicine,undefined

[3] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined

[4] University of Southern California,undefined

[5] Bristol-Myers Squibb,undefined

[6] Yale University School of Medicine and Yale Cancer Center,undefined

来源：

Journal of Translational Medicine | / 12卷 / Suppl 1期

关键词：

Ipilimumab; Tumor Infiltrate Lymphocyte; Advanced Melanoma; Myeloid Derive Suppressor Cell; Absolute Lymphocyte Count;

D O I：

10.1186/1479-5876-12-S1-O8

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
Hamanishi, Junzo
Mandai, Masaki
Ikeda, Takafumi
Minami, Manabu
Kawaguchi, Atsushi
Matsumura, Noriomi
Abiko, Kaoru
Baba, Tsukasa
Yamaguchi, Ken
Ueda, Akihiko
Kanai, Masashi
Mori, Yukiko
Matsumoto, Shigemi
Murayama, Toshinori
Chikuma, Shunsuke
Morita, Satoshi
Yokode, Masayuki
Shimizu, Akira
Honjo, Tasuku
Konishi, Ikuo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[22] LONG-TERM SURVIVAL OF IPILIMUMAB-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PROGRAMMED DEATH-1; ANTI-PD-1; BMS-936558; ONO-4538) IN A PHASE I TRIAL
Hodi, Stephen
Sznol, Mario
Kluger, Harriet M.
McDermott, David F.
Carvajal, Richard D.
Lawrence, Donald P.
Topalian, Suzanne L.
Atkins, Michael B.
Powderly, John D.
Sharfman, William H.
Puzanov, Igor
Smith, David C.
Leming, Philip D.
Lipson, Evan J.
Taube, Janis M.
Anders, Robert A.
Horak, Christine E.
Kollia, Georgia
Gupta, Ashok
Sosman, Jeffrey A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 177 - 177
[23] First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
Gettinger, Scott N.
Shepherd, Frances A.
Antonia, Scott Joseph
Brahmer, Julie R.
Chow, Laura Quan Man
Juergens, Rosalyn A.
Borghaei, Hossein
Shen, Yun
Harbison, Christopher
Alaparthy, Suresh
Chen, Allen C.
Rizvi, Naiyer A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies
Sznol, M.
Powderly, J. D.
Smith, D. C.
Brahmer, J. R.
Drake, C. G.
McDermott, D. F.
Lawrence, D. P.
Wolchok, J. D.
Topalian, S. L.
Lowy, I.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[25] Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
Topalian, Suzanne Louise
Sznol, Mario
Brahmer, Julie R.
McDermott, David F.
Smith, David C.
Gettinger, Scott N.
Taube, Janis M.
Drake, Charles G.
Pardoll, Drew M.
Powderly, John D.
Carvajal, Richard D.
Sosman, Jeffrey Alan
Atkins, Michael B.
Antonia, Scott J.
Spigel, David R.
Lawrence, Donald P.
Kollia, Georgia
Gupta, Ashok Kumar
Wigginton, Jon M.
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[26] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
Kluger, H.
Sznol, M.
Callahan, M.
Postow, M.
Gordon, R.
Segal, N. H.
Rizvi, N.
Lesokhin, A.
Atkins, M. B.
Kirkwood, J.
Burke, M.
Ralabate, A.
Rivera, A.
Kronenberg, S.
Agunwamba, B. U.
Feely, W.
Hong, Q.
Krishnan, S.
Wolchok, J.
ANNALS OF ONCOLOGY, 2014, 25
[27] Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
Ramalingam, S. S.
Mazieres, J.
Planchard, D.
Stinchcombe, T. E.
Dy, G. K.
Antonia, S. J.
Horn, L.
Lena, H.
Minenza, E.
Mennecier, B.
Otterson, G. A.
Campos, L. T.
Gandara, D. R.
Levy, B. P.
Nair, S. G.
Zalcman, G.
Wolf, J.
Baudelet, C.
Lestini, B. J.
Rizvi, N. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (05): : 1266 - 1267
[28] Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
Antonia, S. J.
Gettinger, S.
Goldman, J.
Chow, L. Q.
Juergens, R.
Borghaei, H.
Brahmer, J. R.
Shen, Y.
Harbison, C.
Chen, A. C.
Ready, N. E.
Rizvi, N. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S33
[29] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
Rizvi, Naiyer A.
Gettinger, Scott N.
Horn, Leora
Gandhi, Leena
Spigel, David R.
Powderly, John D.
Heist, Rebecca S.
Carvajal, Richard D.
Jackman, David M.
Sequist, Lecia V.
Smith, David C.
Leming, Philip D.
Topalian, Suzanne L.
Hodi, F. Stephen
Sznol, Mario
Harbison, Christopher T.
Kollia, Georgia D.
Brahmer, Julie R.
Antonia, Scott J.
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S152
[30] ASSOCIATION OF TUMOR PD-L1 EXPRESSION AND IMMUNE BIOMARKERS WITH CLINICAL ACTIVITY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538)
Antonia, Scott J.
Grosso, Joseph F.
Horak, Christine E.
Harbison, Christopher T.
Kurland, John F.
Inzunza, H. David
Gupta, Ashok
Sankar, Vindira
Park, Jong-Soon
Jure-Kunkel, Maria
Novotny, James
Cogswell, John
Zhang, Xiaoling
Phillips, Therese
Simmons, Pauline
Simon, Jason
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S907 - S908

← 1 2 3 4 5 →